Head-to-head · WeighScore
Spry vs WeightCare
The verdict
WeightCare takes it — 58.6/100 to 56.8/100, but only just.
WeightCare grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightCare offers compounded semaglutide ($249–$399/mo) and tirzepatide ($349/mo) dispensed by FDA-registered, PCAB-accredited pharmacies. Spry is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Spry | WeightCare |
|---|---|---|
| WeighScore | 56.8/100 | 58.6/100 |
| Grade | C | C |
| Scorecard rank | #409 | #368 |
| Semaglutide | $199/mo (starting dose, compounded) | $399/mo |
| Tirzepatide | $299/mo (starting dose, compounded) | $499/mo (15 mg dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #409 · C
Strengths
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
Where it loses points
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #368 · C
Strengths
- PCAB-accredited pharmacy partners — strongest pharmacy quality signal
- Quality testing: potency and sterility per USP 797 standards
- 85,000+ members since 2022 — established patient base
- Multiple program tiers for semaglutide
- Health coaching, dietitians, fitness trainers included
Where it loses points
- No LegitScript certification on the site itself
- State availability not explicitly listed
- Compounded only — no brand-name options
- Semaglutide runs $215-$399/mo and tirzepatide $275-$499/mo depending on plan length and dose
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.